an article on the meta-analysis of RCTs [6], which was presented at the workshop and published in Lancet Diabetes and Endocrinology in 2019, as well as four articles on the post-hoc studies of RCTs of SGLT-2 inhibitors and glucagon-like peptide-1 (GLP-1) analogs [30–33], an article on an RCT of a mineralocorticoid receptor (MR) antagonist [23], and an article on a meta-analysis on IgA nephropathy [34], which were published after the workshop. Here, NR3C2 is linked to diabetes mellitus.